of hepatic parenchymal cells and our finding that it directly mediates endocytosis of model remnant lipoproteins. [18] [19] [20] These results were extended by the demonstration that syndecan-1 knockout mice exhibit substantially impaired postprandial remnant lipoprotein clearance. 21 Thus, the syndecan-1 heparan sulfate proteoglycan is a major hepatic receptor for remnant lipoproteins. 18, 19, 21 Moreover, we extensively characterized the endocytic pathway of syndecan-1 that is triggered when it binds large, multivalent lipoproteins, such as C-TRLs. 18, 19, 22 A crucial early step is clustering of syndecan-1, which triggers its movement into cholesterol-rich, detergent-insoluble membrane microdomains (rafts), independent of coated pits. 19, 22 Two families of proteins-caveolins and flotillins-have been implicated in the formation of specific subsets of rafts. 23, 24 Moreover, caveolins and flotillins have both been implicated in membrane internalization and endocytosis. [24] [25] [26] Caveolarmediated endocytosis has been linked to the Src kinase, 27 and flotillin-mediated endocytosis was reported to involve Fyn. 28 Both Src and Fyn are members of the Src family of kinases, a class of enzymes that we identified to participate in syndecan-1-mediated endocytosis. 22 Flotillins were implicated in general proteoglycan internalization, without identifying which species of proteoglycan. 29 Importantly, caveolins and flotillins segregate into distinct regions of the plasma membrane, with distinct ultrastructural morphologies and different pathways for endocytosis. 24 In the current study, we sought to determine whether either caveolins or flotillins participate in syndecan-1-mediated endocytosis of C-TRLs. Surprisingly, we found that syndecan-1-mediated endocytosis of multivalent lipoproteins depends specifically on FLOT1 (flotillin-1) and not on CAV1 (caveolin-1). Importantly, FLOT1 expression is suppressed in the livers of hyperphagic, obese, T2DM KKA y mice, and their diabetic dyslipoproteinemia can be substantially improved by an adenoviral construct to restore hepatic FLOT1 expression to normal levels.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

FLOT1, but Not CAV1, Associates With Syndecan-1 in a Dynamic Fashion That Is Sensitive to Ligand Binding
We began with coimmunoprecipitations using syndecan-1 as bait. To move syndecan-1 into rafts, we added a model multivalent ligand, lipoprotein lipase (LpL)-enriched methylated LDL (mLDL [methylated LDL]+LpL), to cultured McArdle hepatocytes, which express endogenous syndecan-1. The ligand was added 0 to 5 hours before harvesting the cells. The upper 2 immunoblots in Figure 1A show modest, but easily detectable, baseline association of FLOT1 with syndecan-1 (immunoblot of FLOT1 at 0 hour), consistent with the presence of a minority of unclustered syndecan-1 in rafts. 19 Incubation of cells with mLDL+LpL caused the association of FLOT1 with syndecan-1 to became stronger, peaking at 2 hours after the addition of the multivalent ligand. Incubations longer than 2 hours caused the signals for both FLOT1 and syndecan-1 to decrease in the immunoprecipitates. This timing is consistent with our previous demonstrations that it takes over an hour for the movement of syndecan-1 ligands into lysosomes and then lysosomal-mediated destruction of these ligands. 18 Nevertheless, we had not previously examined whether syndecan-1 recycles back to the cell surface or whether it becomes destroyed in the lysosomes with its ligands. The lower 3 immunoblots in Figure 1A show time-dependent loss of FLOT1 and syndecan-1, but not GAPDH, from wholecell homogenates from the same experiment. Moreover, natural multivalent ligands for syndecan-1, namely, human VLDL (very-low-density lipoprotein; Figure 1B ) and murine VLDL ( Figure I in the online-only Data Supplement), also provoked concurrent loss of these 2 molecules from McArdle hepatocytes starting after ≈2 hours of incubation.
We next studied our FcR-Synd1 chimera, which we had made by linking the ectodomain of the IgG Fc receptor Ia to the transmembrane and cytoplasmic domains of human syndecan-1. By several criteria, we had previously shown that endocytosis via FcR-Synd1 after clustering is identical to endocytosis of multivalent ligands via syndecan-1, thereby indicating a dependence on their shared domains. 18, 19, 22, 30 Figure 1C shows essentially the same pattern for the FcRSynd1 chimera that we saw with syndecan-1 in Figure 1A namely, association with FLOT1 in a dynamic fashion that is sensitive to ligand binding and clustering. These results implicate the transmembrane and cytoplasmic domains of syndecan-1 in the association with FLOT1 after clustering and movement into rafts. Likewise, after 2 hours, the signals for the chimera and FLOT1 fade from immunoprecipitates of FcR-Synd1 and from whole-cell homogenates ( Figure 1C) .
To assess the specificity of the association of FLOT1 with syndecan-1, we immunoprecipitated FLOT1 and then immunoblotted for syndecan-1, the LDLR, and the LRP1 (LDLR-related protein-1). Figure 1D confirms the association of FLOT1 with syndecan-1 in a dynamic fashion that is , associates with syndecan-1 in a dynamic fashion that is sensitive to ligand binding. A, Association of FLOT1 with syndecan-1 in the basal state and after syndecan-1 binds a multivalent ligand. Lipoprotein lipase (LpL)-enriched mLDL (methylated low-density lipoprotein) was added to untransfected McArdle hepatocytes at the indicated times before harvest. All cells were plated simultaneously and then harvested simultaneously. A portion of the cellular extracts was used for immunoprecipitation of syndecan-1 (IP: SDC1) as described in Methods, and then the IP pellets were subjected to electrophoretic separation. The upper 2 immunoblots were performed to detect FLOT1 (IB: FLOT1) and then to verify immunoprecipitation and evaluate the loaded material, the same membranes were stripped and reprobed to detect syndecan-1 (IB: SDC1). The lower 3 immunoblots show the contents of FLOT1, syndecan-1, and GAPDH in whole-cell homogenates from the same experiment, that is, the starting material for each of the coimmunoprecipitations. B, Human VLDL (very-low-density lipoprotein), a natural multivalent ligand for syndecan-1, drives concurrent loss of both syndecan-1 and FLOT1 in cultured hepatocytes. Human VLDL was applied at 25 µg protein/mL to untransfected cultured McArdle cells at the indicated times before harvest. All cells were plated simultaneously and harvested simultaneously. Shown are immunoblots for syndecan-1, FLOT1, and GAPDH in whole-cell extracts. C, Association of FLOT1 with FcR-Synd1, a chimeric receptor consisting of the ectodomain of the IgG Fc receptor Ia linked to the transmembrane and cytoplasmic domains of syndecan-1. We studied the FcRSynd1 chimera in the basal state and after clustering. McArdle hepatocytes stably expressing the FcR-Synd1 chimera were treated with ligand plus our clustering agent (IgG+C), as described in the Methods, and then incubated for the indicated times. A portion of the cellular extracts was used for immunoprecipitation of FcR-Synd1 (IP: FcR-Synd1). The upper 2 immunoblots were performed to detect FLOT1, and then the same membranes were stripped and reprobed to detect FcR-Synd1. The lower 3 immunoblots show the contents of FLOT1, FcR-Synd1, and GAPDH in whole-cell homogenates from the same experiment. D, Robust association of FLOT1 with syndecan-1 but not with other receptors, as assessed by immunoprecipitation of FLOT1. Untransfected McArdle hepatocytes were treated as in A, that is, incubated with LpL-enriched mLDL for the indicated times and then used to prepare cellular homogenates. Here, FLOT1 rather than syndecan-1 was immunoprecipitated (IP: FLOT1), followed by immunoblotting (IB) to detect syndecan-1, the LDLR (LDL receptor), and the LRP1 (LDLR-related protein-1). The lower 4 immunoblots show the contents of syndecan-1, LDLR, LRP1, and GAPDH in whole-cell homogenates from the same experiment. E, No detectable association of CAV1 with syndecan-1 and no loss of CAV1 during syndecan-1-mediated endocytosis. Untransfected McArdle hepatocytes were treated as in A and D, that is, incubated with LpL-enriched mLDL for the indicated times and then used to prepare cellular homogenates. Syndecan-1 was immunoprecipitated (IP: SDC1), followed by immunoblotting to detect CAV1 (IB: CAV1), and then the same membranes were stripped and reprobed to detect syndecan-1 (IB: SDC1). The lower 3 immunoblots show the contents of CAV1, syndecan-1, and GAPDH in whole-cell homogenates from the same experiment. F, Cofractionation of syndecan-1 and FLOT1 in detergent-insoluble, buoyant membrane domains (rafts). Untransfected McArdle hepatocytes were treated with LpL-enriched mLDL for 1 h to cluster syndecan-1, and then lyzed in ice-cold 1% Triton X-100 buffer to disrupt nonraft membranes. Residual detergent-insoluble cellular material was homogenized and then fractionated by ultracentrifugation across a sucrose gradient, as described in the Methods. Shown are immunoblots (proteins) and dot-blots (G M1 ) of sequential fractions from the top (buoyant lipid rafts) to the bottom of the gradient. Ganglioside G M1 is a marker for lipid rafts. Data are representative of 3 independent experiments. C indicates a whole-cell homogenate used as a positive control for the immunoblots and dot-blots; and P, the cell pellet at the bottom of the ultracentrifugation tube. sensitive to multivalent ligand binding. Figure 1D indicates no association of LRP1 with FLOT1 and a weak association of LDLR with FLOT1. These results are consistent with our prior finding of an unexpected consensus motif shared by the transmembrane domains of syndecan-1 and the LDLR, but absent from the transmembrane domains of LRP1 and the other members of the LDLR gene family. 31 In contrast to Figure 1A and 1D, Figure 1E shows that CAV1 does not coimmunoprecipitate with syndecan-1, even after addition of a multivalent ligand (upper immunoblots). Both CAV1 and syndecan-1 are easily detected in wholecell homogenates, and, importantly, the signal for cellular CAV1 is unaffected by the binding of a multivalent ligand to syndecan-1 and the subsequent loss of cellular syndecan-1 ( Figure 1E , lower immunoblots).
As an independent method to assess the relationships between syndecan-1, FLOT1, and CAV1, we incubated McArdle hepatocytes with mLDL+LpL for 1 hour to cluster syndecan-1, lysed the cells in cold 1% Triton X-100 to disrupt nonraft membranes, and then fractionated the remaining detergent-insoluble membranes by ultracentrifugation across a sucrose gradient, as described in the Methods. Figure 1F shows that this technique almost entirely separates FLOT1-containing rafts (fractions 2-4) from CAV1-containing rafts (predominantly fractions 6-10). Syndecan-1 appears in 2 regions of the gradient: fractions 2 to 4, that is, copurifying with FLOT1, and fractions 9 to 12, that is, only partially overlapping with the major CAV1-containing fractions.
FLOT1, but Not CAV1, Participates in Endocytosis and Lysosomal Targeting of Syndecan-1 With Its Multivalent Ligands
Next, using siRNAs to suppress the expression of FLOT1 or CAV1, we examined the roles of these molecules in syndecan-1-mediated endocytosis. Figure 2A shows that knockdown of FLOT1 had no effect on cell surface binding of VLDL, a physiological, multivalent ligand for syndecan-1, but impaired the internalization, degradation, and hence total cellular catabolism of this ligand. Figure 2B shows the same effects for LpL-enriched Figure 2C shows a decrease in the signal for syndecan-1 in control cells by 5 hours after the addition of a multivalent ligand for syndecan-1. This effect was abolished by knockdown of FLOT1, consistent with impaired endocytosis and impaired movement into lysosomes for destruction.
The upper immunoblots in Figure 2D show that chloroquine, which inhibits lysosomal acidification and endosomallysosomal fusion, completely blocks cellular loss of both FLOT1 and syndecan-1 during catabolism of a multivalent ligand. The lower immunoblots in Figure 2D show that, in the absence of chloroquine, mLDL+LpL causes syndecan-1 and FLOT1 to move from their predominant localization in the plasma membrane fraction at 0 hour, to substantial lysosomal (LY) localization at 2 hours. By 4 hours, total signals for both proteins have attenuated. The addition of chloroquine blocked ligand-induced movement of syndecan-1 and FLOT1 into lysosomes, as well as ligand-induced loss of the 2 proteins. Figure 2E indicates that CAV1 knockdown does not affect cell surface binding, internalization, degradation, or total cellular catabolism of LpL-enriched 125 I-labeled mLDL, in contrast to the effects of FLOT1 knockdown in Figure 2B . Figure III in the online-only Data Supplement shows that individual knockdowns of FLOT1 and CAV1 substantially and similarly disrupted overall raft structure, but only the knockdown of FLOT1 excluded syndecan-1 from the most buoyant raft fractions. Two additional molecules, namely, Fyn, a member of the Src family of kinases, and the glycosylphosphatidylinositol-anchored form of cluster of differentiation (CD)55, another raft marker, also depend on FLOT1 to associate with raft fractions, with no apparent dependence on CAV1 ( Figure III in the online-only Data Supplement).
T2DM in KKA y Mice Suppresses Hepatic Levels of FLOT1 in Association With Hypertriglyceridemia
In previous studies, we identified the sulfatase-2 (SULF2) as an endogenous inhibitor of the binding of C-TRLs to syndecan-1, 32 and we implicated abnormal hepatic overexpression of SULF2 in postprandial dyslipoproteinemia in T2DM db/db mice. 33 Moreover, we and others identified a human SULF2 gene polymorphism that associates with improved postprandial fat tolerance in T2DM patients 34 and in healthy subjects. 35 Surprisingly, we now found that hepatic expression levels of SULF2 protein in another widely used model of hyperphagia, T2DM, and metabolic dyslipoproteinemia-the KKA y mouse 7, [36] [37] [38] -are not elevated compared with levels in nondiabetic KK littermate controls ( Figure IV in the online-only Data Supplement). To explore the molecular basis for metabolic dyslipidemia in KKA y mice, 36, 37 we examined the expression of FLOT1 in their livers. Figure 3A shows a striking deficiency of FLOT1 protein in livers from T2DM KKA y mice compared with nondiabetic KK controls. Figure V in the online-only Data Supplement extends this finding to db/db mice, while also confirming their hepatic overexpression of SULF2. Figure 3B indicates a marked deficiency of Flot1 mRNA in KKA y livers. The T2DM KKA y mice have normal hepatic levels of syndecan-1 ( Figure 3C ) and no deficiency of the mRNA for the syndecan-1 core protein (Sdc1; Figure 3D ). Similar to previous data in obese Zucker rats 39 and T2DM db/db mice, 32 hepatic Sdc1 mRNA levels in T2DM KKA y livers showed a trend to higher values than those in KK controls, although here the difference was not statistically significant. Importantly, coimmunoprecipitations reveal that far less FLOT1 protein associates with syndecan-1 in the livers of KKA y mice than does in control KK livers ( Figure 3E ). To assess possible relationships between plasma lipoprotein concentrations and hepatic Flot1 mRNA levels, we examined statistical correlations in T2DM KKA y and control KK mice. A graph of fasting plasma triglyceride concentrations versus hepatic 
(2-tailed Student t test). C, D,
The same liver samples used in A and B were analyzed for their contents of the syndecan-1 heparan sulfate proteoglycan (HSPG) by immunoblot (C) and the syndecan-1 core protein mRNA by qRT-PCR (D, P>0.5 by the 2-tailed Student t test). E, Syndecan-1 was immunoprecipitated from mouse liver extracts (IP: SDC1, with nonimmune IgG as the negative control), and the IP pellets were subjected to electrophoretic separation. The upper 2 immunoblots were performed to detect FLOT1 (IB: FLOT1) in the immunoprecipitate, and then the same membranes were stripped and reprobed to detect syndecan-1 (IB: SDC1). The lower 3 immunoblots show the contents of syndecan-1, FLOT1, and GAPDH in liver tissue homogenates from the same experiment, that is, the starting material for each of the coimmunoprecipitations, arranged in the same order as in the upper immunoblots. F, Plot of plasma triglyceride concentrations versus hepatic Flot1 mRNA levels for all control KK mice and all T2DM KKA y mice. All data in this figure are representatives of 3 independent experiments. January 2018 Flot1 mRNA levels showed complete segregation of T2DM KKA y mice, in the upper left-hand corner, from control KK mice, which are all in the lower right-hand sector ( Figure 3F ).
The First Hydrophobic Hairpin of FLOT1 Is Required for Association With Syndecan-1 in Cultured Liver Cells
To identify molecular determinants within FLOT1 responsible for its interaction with syndecan-1, as well as the functional importance of this interaction, we sought to make 2 plasmid constructs, one encoding wild-type (WT, unmutated) mouse FLOT1, and the other a site-directed mutant (Mut) of mouse FLOT1 that would no longer associate with syndecan-1. Figure 4A shows schematics of 2 constructs in the pcDNA 3 (−) expression plasmid that we prepared to test in cultured cells. The upper schematic summarizes the structure of WT FLOT1, which includes an N-terminal prohibitin homology domain (also known as the Stomatin, Prohibitin, Flotillin, and High frequency of lysogenization-K/C [SPFH] domain). The prohibitin homology domain is thought to mediate membrane association via a single palmitoylation site at Cys34 and 2 putative hydrophobic hairpins that are thought to insert into the inner leaflet of the plasma membrane. 40, 41 The C terminus of FLOT1 contains a conserved flotillin domain involved in oligomerization and raft formation. 41, 42 The lower schematic in Figure 4A summarizes our site-directed FLOT1 mutant, in which we converted the first hydrophobic hairpin, including the palmitoylation site, into a run of 27 consecutive alanines (the first residue of the unmutated hairpin is already an alanine). A truncated epitopetagged mouse FLOT1 construct missing the first 35 residues was previously shown to localize to the plasma membrane in nonraft domains. 42 Each of our expression constructs, pcDNA 3 -Flot1(WT)-Flag and pcDNA 3 -Flot1(Mut)-Flag, was linked at the 3′ end of the coding region (C terminus of the protein) to a sequence encoding the Flag epitope tag (DYKDDDDK). 43 A control plasmid encoded only the Flag epitope tag (pcDNA 3 -Flag, not shown schematically).
The upper immunoblots in Figure 4B show that transient transfection of the pcDNA 3 The PHB domain contains a single palmitoylation site at Cys34 and 2 putative hydrophobic hairpins that are thought to insert into the inner leaflet of the plasma membrane. The lower schematic summarizes our site-directed FLOT1 mutant (Mut), in which we converted the first hydrophobic hairpin, including the palmitoylation site, into a run of 27 consecutive alanines (the first residue of the unmutated hairpin is already an alanine). Each of these expression constructs was linked at the 3′ end of the coding region (C terminus of the protein) to a sequencing encoding the Flag epitope tag (DYKDDDDK). These coding sequences were placed into the pcDNA 3 (−) expression vector to produce pcDNA 3 Figure 4C show the contents of the Flag epitope, syndecan-1, and GAPDH in whole-cell homogenates from the same experiment, that is, -gfp, not shown schematically) . B-F, Adenoviral particles (10 9 plaque-forming units [pfu] per mouse) or phosphate-buffered saline (PBS) were administrated via caudal vein to 12-wk-old phenotypically lean KK mice and their centrally obese, T2DM KKA y littermates, as indicated. Four weeks after injection, livers and blood plasma were collected. Immunoblots of liver extracts were performed in triplicate to assess contents of immunoreactive FLOT1 protein (B), syndecan-1 (SDC1; C), and, as a loading control, GAPDH (B, C). Each lane represents a sample from a different animal. In D, syndecan-1 was immunoprecipitated from mouse liver extracts (IP: SDC1), and the IP pellets were subjected to electrophoretic separation. Shown are immunoblots to detect immunoreactive FLOT1 (IB: FLOT1), and then the same membranes were stripped and reprobed to detect syndecan-1 (IB: SDC1). E, F, Triglyceride and LDL (low-density lipoprotein) cholesterol concentrations, respectively, in fasting plasma samples 4 weeks after administration of adenoviruses or saline. Displayed are means±SEMs, n=6 per group. P<0.001 by ANOVA; **P<0.01 versus saline-treated KKA y (Dunnett q′ test). Data in B-F are representative of 3 independent experiments. the starting material for the coimmunoprecipitations in the upper immunoblots of Figure 4C . Figure 5A shows schematics of adenoviral constructs analogous to the plasmid constructs of Figure 4A , to drive expression of WT or mutated FLOT1 in liver in vivo [AdVFlot1(WT), AdV-Flot1(Mut); not shown schematically is our control adenovirus, AdV-gfp, that drives expression of green fluorescent protein]. Administration of 10 9 plaqueforming units per injection of either of the 2 FLOT1 adenoviral constructs to individual KKA y mice, followed by 4 weeks to allow expression, was able to normalize hepatic content of immunoreactive FLOT1 protein ( Figure 5B) . Expression of WT FLOT1, but not the mutant, caused a moderate decrease in hepatic syndecan-1 ( Figure 5C ), presumably reflecting enhanced trafficking to lysosomes. Similar to our results in cultured hepatocytes (Figure 4) , only WT FLOT1 in the liver coimmunoprecipitated with syndecan-1; the mutated FLOT1 did not ( Figure 5D ).
Restoration of WT FLOT1 Expression in Livers of T2DM KKA y Mice Corrects Their Fasting Hypertriglyceridemia
Next, we examined metabolic effects of the FLOT1 adenoviral constructs in T2DM KKA y mice. Controls included phosphate-buffered saline-treated or AdV-gfp-treated T2DM KKA y mice and phosphate-buffered saline-treated nondiabetic KK mice. These treatments did not affect body weights, hyperglycemia, or HOMA-IR (the homeostatic model assessment of insulin resistance for handling glucose; Table) . There was no significant difference in plasma insulin concentrations in KKA y mice treated with the 2 AdV-Flot1 constructs (Table) . Figure 5E shows the effects of these treatments on fasting plasma triglyceride concentrations. The KKA y mice that we treated with phosphate-buffered saline, Adv-gfp, or AdV-Flot1(Mut) showed statistically indistinguishable levels of hypertriglyceridemia. In contrast, the AdV-Flot1(WT) construct lowered fasting plasma triglyceride levels in KKA y mice by 35%, to achieve values indistinguishable from those in nondiabetic KK mice. Similarly, the AdV-Flot1(WT) construct, but not the AdVFlot1(Mut) adenovirus, corrected plasma nonesterified fatty acid concentrations in KKA y mice to normal levels (Table) . The
AdV-Flot1(WT) construct did not significantly affect fasting plasma LDL cholesterol in KKA y mice ( Figure 5F ).
Restoration of WT FLOT1 Expression in Livers of T2DM KKA y Mice Corrects Their Postprandial Dyslipidemia
Similar to other hyperphagic animals 33, 44 and obese type 2 diabetic humans, 8 T2DM KKA y mice exhibited a substantial impairment in postprandial fat tolerance, indicated here by abnormally large, prolonged excursions in plasma concentrations of triglyceride ( Figure 6A and 6B) and tritium ( Figure 6C and 6D) On the basis of our demonstration of a role for FLOT1 in internalization and degradation of lipoproteins by cultured hepatocytes (Figure 2 ), the most likely explanation for improved postprandial fat tolerance in T2DM KKA y mice after treatment with our AdV-Flot1(WT) construct ( Figure 6 ) is enhanced hepatic lipoprotein clearance. Nevertheless, it is theoretically possible that restoration of WT FLOT1 expression in the liver might influence postprandial C-TRL secretion. To investigate this possibility, we performed another fat tolerance test, but in this experiment, some of the KKA y mice that had received Adv-Flot1(WT) or Adv-Flot1(Mut) were given an intravenous injection of Triton WR1339 to block lipoprotein clearance. Thus, the slope of their plasma triglyceride concentration curves from 0 to 4 hours after a gastric gavage of corn oil can be used to calculate the production rates of lipoprotein triglyceride. The results in Figure VII in the online-only Data Supplement confirm the finding from Figure 6A and 6B that Adv-Flot1(WT), but not Adv-Flot1(Mut), substantially corrects postprandial fat tolerance in T2DM KKA y mice that had not received Triton WR1339. Figure VII in the online-only Data Supplement also shows that this correction occurs without any difference in the postprandial production rate of lipoprotein triglyceride.
Discussion
In the present study, we identified a novel factor, FLOT1, that physically interacts with syndecan-1 and thereby facilitates normal syndecan-1-mediated endocytosis and then lysosomal disposal of C-TRLs. Binding of C-TRLs to syndecan-1 on the surface of liver cells enhances syndecan-1/FLOT1 association. The 2 molecules then traffic together into the lysosomes, implying limited if any recycling back to the cell surface. The interaction requires the transmembrane/cytoplasmic region of syndecan-1 and the N-terminal hydrophobic domain of FLOT1.
Syndecan-1-mediated endocytosis occurs in cholesterolrich membrane microdomains (rafts), 19, 22 and FLOT1 had been identified as a structural component of specific types of rafts. [23] [24] [25] Moreover, FLOT1 interacts with many elements that were previously showed to participate in syndecan-1-mediated endocytosis, 22 such as Src family kinases, 41 cortactin, 45 and the actin cytoskeleton. 41 Consistent with the model of flotillin-assisted endocytosis, in which flotillins facilitate but do not necessarily mediate endocytosis, 46 our knockdowns of FLOT1 slowed, but did not stop, internalization and lysosomal delivery of VLDL or model C-TRLs (Figure 2A and 2B ). Low amounts of residual FLOT1 after knockdown may have also contributed. Significant roles for LDLR gene family members in these knockdown experiments seem unlikely, based on our previous demonstrations that LpL-dependent cellular internalization of lipoproteins is nearly entirely abolished by digesting cells with heparitinase, an enzyme that removes the heparan sulfate side chains of syndecan-1 and other heparan sulfate proteoglycans but does not affect the LDLR or LRP1, 47 as well as other distinctive features of ligand internalization via the syndecan-1 pathway versus coated-pit receptors, such as slower kinetics and an unusual pattern of responses to several inhibitors. 18, 19, 22 Atherogenic dyslipoproteinemia in syndromes of chronic overnutrition has resisted molecular explanation for many years. 12 Our previous systematic survey of proteoglycanrelated gene transcripts on the GLYCOv3 microarray revealed a single hepatic mRNA, Sulf2, that was affected by obesity and T2DM in mice in a way that would impair syndecan-1 function as remnant lipoprotein receptors. 32 Hassing et al 34 and Matikainen et al 35 extended this work by implicating a role for SULF2 in plasma C-TRL accumulation in humans. Our current data add FLOT1 to the short list of molecules that affect syndecan-1-mediated catabolism of C-TRLs in vivo and are dysregulated in T2DM liver to impair syndecan-1 function. Moreover, restoring hepatic FLOT1 expression to normal levels in centrally obese, T2DM KKA y mice significantly corrected their fasting and postprandial dyslipoproteinemia (Figures 5E and 6 ; Figure  VII in the online-only Data Supplement). Of note, our prior work correcting hepatic Sulf2 overexpression in hyperphagic T2DM db/db mice flattened their plasma triglyceride excursions after corn oil gavage, 33 despite our current finding of a dual defect in these mice, that is, hepatic SULF2 overexpression combined with FLOT1 underexpression ( Figure V in the online-only Data Supplement). To resolve the roles of these 2 proteins, the possible involvement of FLOT1 dysregulation in human metabolic dyslipoproteinemia will be a high priority to examine. Interestingly, despite correction of plasma nonesterified fatty acid levels after WT FLOT1 expression in KKA y mice (Table) , there was no improvement in HOMA-IR, which is consistent with a considerable and growing body of literature contradicting the hypothesis of a central role for fatty acids in causing insulin resistance for handling glucose. 7, 48, 49 In addition, our detergent injection study revealed that in vivo restoration of WT FLOT1 did not affect VLDL secretion into plasma ( Figure VII in the online-only Data Supplement), whereas the in vivo rescue of FLOT1 in diabetic animals improved the hepatic clearance of remnant lipoproteins, for both apoB 48 and apoB 100 ( Figure VI in the online-only Data Supplement).
The molecular basis for FLOT1 suppression in the livers of centrally obese, T2DM KKA y mice will be an important topic for future study. Taken together, we have identified a new role for FLOT1 in syndecan-1-mediated lipoprotein catabolism via raft-dependent endocytosis. Low expression of FLOT1 in T2DM liver may contribute to metabolic dyslipoproteinemia.
